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Abstract 
Background: Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) is clinically defined and characterised 
by persistent disabling tiredness and exertional malaise, leading to functional impairment.
Methods: This study introduces the weighted standing time (WST) as a proxy for ME/CFS severity, and investigates 
its behaviour in an Australian cohort. WST was calculated from standing time and subjective standing difficulty data, 
collected via orthostatic intolerance assessments. The distribution of WST for healthy controls and ME/CFS patients 
was correlated with the clinical criteria, as well as pathology and cytokine markers. Included in the WST cytokine anal-
yses were activins A and B, cytokines causally linked to inflammation, and previously demonstrated to separate ME/
CFS from healthy controls. Forty-five ME/CFS patients were recruited from the CFS Discovery Clinic (Victoria) between 
2011 and 2013. Seventeen healthy controls were recruited concurrently and identically assessed.
Results: WST distribution was significantly different between ME/CFS participants and controls, with six diagnostic 
criteria, five analytes and one cytokine also significantly different when comparing severity via WST. On direct com-
parison of ME/CFS to study controls, only serum activin B was significantly elevated, with no significant variation 
observed for a broad range of serum and urine markers, or other serum cytokines.
Conclusions: The enhanced understanding of standing test behaviour to reflect orthostatic intolerance as a ME/CFS 
symptom, and the subsequent calculation of WST, will encourage the greater implementation of this simple test as a 
measure of ME/CFS diagnosis, and symptom severity, to the benefit of improved diagnosis and guidance for potential 
treatments.
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Background
Myalgic Encephalomyelitis/Chronic Fatigue Syndrome 
(ME/CFS) is a clinically defined syndrome characterised 
by persistent and disabling tiredness leading to functional 
impairment. Among the case definitions that existed for 
ME/CFS at the time of this study, the Canadian Criteria 
[1] was considered to be the most comprehensive. It 
defined ME/CFS as four or more symptoms, each of 
which have persisted or recurred during 6 or more con-
secutive months of illness. These symptoms include: 
ongoing and unexplained fatigue, post-exertional malaise 
lasting more than 24 h, and two or more from the defini-
tion of Neurological/Cognitive Manifestations (e.g. cog-
nitive or memory impairment), and at least one symptom 
from two of the following categories, namely, autonomic, 
neuroendocrine, or immune manifestations. Although 
contention surrounds the validity of certain criteria, 
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studies utilising this definition have reported a preva-
lence of between 0.3 and 1.8 percent [2, 3].
The aetiology of ME/CFS is complex and poorly under-
stood. Anecdotally, ME/CFS often begins following an 
acute episode of “flu-like” symptoms including lymphad-
enopathy, fever, malaise, headache and sore throat. Such 
anecdotes are suggestive of infectious agents, particularly 
viruses. Historically, “clusters” or “outbreaks” of ME/CFS 
have been frequently linked to known outbreaks of viral 
illnesses, particularly polio in the 1950s case of the Royal 
Free Hospital Group, or Epstein-Barr virus in the surge 
of ME/CFS diagnoses in Lake Tahoe in the late 1980s 
[4]. This hypothesis has been empirically investigated 
by a prospective study of 256 patients diagnosed with 
Epstein-Barr virus, Q fever or Ross River virus disease, 
which concluded that 11% of the cohort developed ME/
CFS, with similar symptomatology, within 12  months 
of infection [5]. Current empirical associations exist 
between ME/CFS and ten different viruses. It is hypoth-
esised that viruses implicated in the pathogenesis of 
chronic fatigue share two primary features: they cannot 
be fully eradicated by the immune system, perhaps lead-
ing to the chronicity of symptoms, and they can affect the 
central nervous system, potentially accounting for auto-
nomic dysfunction [6, 7].
It is also important to address the relationship between 
immune dysfunction and the degree of ME/CFS symp-
tomatology. Unfortunately, most theories of ME/CFS 
pathogenesis are unable to fully account for the heteroge-
neity of symptoms experienced, nor the severity of these 
symptoms. This often leads to the misleading view of 
ME/CFS as a psychogenic disorder because sufficient his-
tological or biochemical aetiology cannot be identified. 
Recent research is increasingly identifying sub-groups of 
ME/CFS populations, who are characterised by dysfunc-
tion in particular domains, compared to other patients 
who also meet the ME/CFS criteria [8, 9].
The standing test is used by clinicians to assess the 
degree of orthostatic intolerance (OI) in a variety of con-
ditions, including ME/CFS, and for the assessment of 
cardiovascular response [10, 11], as well as to study of 
orthostatic hypotension and tachycardia [12]. In addi-
tion to time measurements, the standing test can include 
a subjective score of standing difficulty, which reflects an 
array of symptoms, for example pre-syncope and pain.
Measures of standing difficulty or pain are often ordi-
nal rather than interval or ratio-scaled due to the subjec-
tive and individualised nature of the experience being 
measured, and in cases where the subject cannot answer 
for themselves (for example animal clinical scores [13]). 
The standing time as currently recorded represents a sin-
gle-category scale with ten levels (2–20  min). There are 
ordinal pain scales based on pictures, developed for use 
with pre-numerate children [14].
Weighting or adjusting one measurement by another 
is well known in the quality of life literature, with Dis-
ability Adjusted Life Years [15] and Quality Adjusted Life 
Years [16] both being constructed by taking a quantita-
tive measurement (years of life) and multiplying it by a 
factor less than one that represents the severity of disabil-
ity or the reduction in quality. Some concerns have been 
expressed about the value of weighting years of life meas-
urements [17]. While critics do acknowledge that the face 
validity and intuitive appeal to weighting a rating by an 
importance, they raise concerns about the high correla-
tion between weighted and unweighted ratings, and the 
additional complications introduced by multiplying a rat-
ing by an importance.
Since the distribution of standing time has not been 
widely explored, there is value in investigating the dis-
tribution of the unweighted standing time in the first 
instance. Furthermore, it is not yet known whether 
weighting the standing time could improve the proper-
ties of the unweighted standing time, in particular the 
ability of the standing test to delineate between levels of 
ME/CFS severity in patients. This study addresses these 
questions.
Methods
Aim
The aim of this paper is to introduce the weighted stand-
ing time (WST) as a proxy for ME/CFS severity, involving 
an Australian cohort recruited from the greater Mel-
bourne region. Questions addressed to achieve this aim 
comprise the distribution of WST for healthy controls 
and patients with ME/CFS, the relationship between 
WST and Canadian criteria for ME/CFS diagnosis, and 
the relationship between WST and serum/urine analytes 
collected both for pathology testing required for screen-
ing and monitoring patients, as well as serum cytokine 
profiles.
Patient cohort
Participants were referred to, or voluntarily presented 
to, the CFS Discovery Clinic (Donvale, Victoria) between 
2011 and 2013. Patients were included if they fulfilled 
the Canadian Diagnostic ME/CFS criteria [1], and con-
sented to physical examination and biochemical evalu-
ation. Forty-seven consecutive ME/CFS participants 
were recruited to the study, with two female volunteers 
excluded from the final cohort due to exceeding the age 
criteria. One of the remaining 45 patients had a missing 
standing time measurement (mins), which was estimated 
using median imputation, allowing the participant to 
continue in the study. There were 17 control volunteers 
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recruited from the same area of Melbourne, who were 
in general good health, but not residing with a cur-
rent patient, nor with a ME/CFS family history. The age 
range for ME/CFS and healthy control participants was 
18–65 years, with a female to male ratio of approximately 
4:1.
Inventories
All research participants (ME/CFS and healthy study 
controls) completed a full history, physical examination 
and survey assessment to ascertain their profile under 
the Canadian Criteria for ME/CFS diagnosis. This gener-
ated 48 binary variables across neurological, gut, immune 
activity, pain and so on, as prescribed by the Canadian 
Consensus Criteria [1], with each criterion scored as 
0 or 1 (absent or present) from the clinical assessment, 
or questionnaire responses. This study commenced just 
prior to the publication of the International Criteria [18]; 
therefore, it continued with diagnosis by the Canadian 
Criteria for the project duration.
As a minimum diagnostic requirement of ME/CFS, 
activity limiting fatigue must have been present for at 
least 6  months, and must have featured post-exertional 
fatigue (“payback”). A comprehensive profile of addi-
tional criteria symptoms was explored, including cogni-
tive and neurological function, immune function, sleep, 
gastrointestinal function, pain and autonomic responses. 
Screening symptoms and related physical signs of signifi-
cance are presented by system in Additional file 1: Table 
S1. In addition to Canadian Criteria screening, all partici-
pants were asked to complete a Depression, Anxiety and 
Stress Scale (DASS) [19]. No participants were excluded 
due to DASS results.
Weighted standing time
The CFS Discovery orthostatic intolerance (standing test) 
protocol is described in detail elsewhere [10]. Briefly, par-
ticipants were required to stand, unaided for a maximum 
of 20 min after a period of repose necessary for baseline 
(pre-standing) measurements. Heart rate, blood pressure 
and oxygen saturations were measured at baseline, and 
subsequently every 2  min during standing. Parameters 
were measured at the end of the task (either capped at 
20  min, or when the participant could no longer con-
tinue) and after 3 min of rest following task completion. A 
difficulty score was also recorded by the nurse, a subjec-
tive measure of how difficult the patient found the stand-
ing test. A score between 0 and 10 was recorded (0 = no 
difficulty standing, 10 = support required to stand, pre-
syncope). For this study, two further scores were added, 
with a subjective score of 12 indicating standing difficulty 
to the point that the standing test was terminated at less 
than 20 min (but greater than 10 min), and a score of 14 
represented the most extreme difficulty where standing 
was only possible for 10 min, or less.
With the majority of the ME/CFS cohort achiev-
ing a standing time of 20 min, comparisons of standing 
times for ME/CFS and healthy control cohorts were not 
informative. To weight the standing time in relation to 
subjective standing difficulty, and produce a single fatigue 
response variable, the time standing (maximum 20 min, 
measured at 2 min intervals) and standing difficulty were 
combined to produce one measure called the “Weighted 
Standing Time” (WST). The WST (minutes) was calcu-
lated by the following equation:
WST was calculated for each ME/CFS and study con-
trol participant, and the WST score (minutes) used 
thereafter as a measurable proxy for fatigue severity. For 
statistical analyses, WST was assigned as the response 
(dependent) variable for comparisons of blood, urine and 
cytokines.
Statistical analysis
(i) Clinical (Canadian) criteria—Factor analysis of a tet-
rachoric correlation matrix (varimax rotation) was con-
ducted to identify significant clinical factors under these 
diagnostic criteria, as represented by the percentage vari-
ance explained by the factor loadings. Tetrachoric corre-
lation allows the analysis of data containing categorical 
measures, for example “yes” or “no” to the presence of 
diagnostic symptom under the Canadian Criteria. Analy-
sis of variance was used to determine the statistical dif-
ference in factor scores across the WST classes (Table 1).
Factor analyses (FA) were performed using the 
psych() and lattice() libraries of R3.3.0 [20–22], 
applying the FA method described by Tabachnick and 
Fidell [23]. The individual criteria of “Fatigue ≥ 6 months”, 
“Limited Activity” and “Payback” were omitted from the 
factor analysis due to 100% of the patients and 0% of the 
healthy controls reporting their presence. Details of the 
factors and their loadings are included in Additional 
file 1: Tables S2–S10.
(ii) Analytes—For the range of blood, urine and 
cytokine markers compared for ME/CFS versus study 
(healthy) controls, descriptive statistics were expressed 
as mean (± standard deviation) for continuous variables, 
and as proportions (%) for categorical variables. Two 
sample tests (Mann–Whitney U) were used to determine 
whether study (healthy) control and ME/CFS partici-
pants could be separated statistically at p < 0.05.
(iii) WST severity scale—The WST was used to define 
three categories of severity for ME/CFS: mild, moderate 
and severe. Together with the healthy study controls as 
Weighted standing time (WST) = Time standing (mins)
× (1− (Difficulty/14)).
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a distinct WST category, analysis of variance (ANOVA) 
and follow-up Tukey Highest Significant Difference tests 
were applied to determine whether statistical significance 
(p < 0.05) was achieved for individual analytes between 
the controls and the three levels of ME/CFS severity, 
as defined by WST (Table 2 and Additional file 1: Table 
S11).
Because of skewness in both standing time (ST) and 
weighted standing time (WST) data, Wilcoxon signed 
rank tests were employed to investigate significance 
for both median ST and median WST between groups 
(Table  2). The Wilcoxon signed rank test, Mann–Whit-
ney U, one-way ANOVA and follow-up tests were con-
ducted using R 3.3.0 [20].
Identification of diagnostic criteria that discriminate 
between categories of ME/CFS were done on the basis 
that no more than three of the healthy-mild patients 
recorded presence of the criterion.
Pathology and cytokine testing
All participant serum, blood and urine analyses were 
conducted by HealthScope Pathology (now Austral-
ian Clinical Laboratories), Clayton Victoria, Australia. 
Activin proteins and cytokines were measured in serum, 
as described previously [24–26].
Human ethics approval
All research participants included in this study provided 
full, signed consent as dictated by the guidelines of the 
Table 1 Symptoms and related physical signs based on the Canadian Criteria for ME/CFS diagnosis, presented by class, 
and as assessed at the CFS Discovery Clinic
Identification of significant diagnostic criteria responses via factor analysis of a tetrachoric correlation matrix
Based on Canadian Criteria [1]
* Percentage variance explained, derived from factor analysis of tetrachoric correlation matrix across all CFS/ME severity classes, including healthy study controls
** p values calculated from ANOVA of factor scores across four classes of severity defined by weighted standing time (WST)
# No (0%) healthy controls reported a minimum of 6-months fatigue, or post-exertional fatigue/malaise
Canadian criteria symptom 
classes
Role in CFS/ME diagnosis Specific symptoms identified Factor analysis (% variance)* 
ANOVA (p value)**
Post-exertional malaise and fatigue Mandatory Fatigue, malaise and/or pain post 
effort ≥ 24-h recovery
All symptoms are mandatory (100%)#
Minimum 6-months fatigue Mandatory ≥ 6-months unexplained fatigue Symptom mandatory (100%)#
Sleep disorder Mandatory Difficulty going to sleep
Sleep during day
62% (p < 0.0001)
Pain Mandatory Pain (any region)
Headache
87% (p < 0.0001)
71% (p = 0.118)
Neurological/cognitive manifesta-
tions
≥ 2 criteria required Light, sound and/or smell sensitivity
Confusion
62% (p < 0.0001)
38% (p < 0.0001)
Autonomic
Breathless 58% (p < 0.0001)
Arrhythmia 42% (p < 0.0001)
Autonomic/neuroendocrine/
immune manifestations
≥ 1 criteria for 2 of the 3 categories 
required
Gut
Bloating, abdominal pain, diarrhoea 40% (p < 0.0001)
Neuroendocrine
Hot/Cold flushes 73% (p < 0.0001)
Immune
Tender glands, flulike symptoms, 
chemical (allergy) sensitivity
45% (p < 0.0001)
Table 2 Summary statistics for standing time (ST) and weighted standing time (WST) for the ME/CFS and healthy study 
control groups
a Wilcoxon signed rank (WSR) test (p < 0.05)
Standing criteria (median) CFS (n = 45) (min) Healthy (n = 17) (min) p value
Standing time (IQR) 20 (20–14 = 6) 20 (20–20 = 0) p = 0.0106a
WST (IQR) 10 (14.29–4 = 10.29) 18.57 (14.29–4 = 10.29) p < 0.0001a
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ANU Human Research Ethics Committee (ANU-HREC). 
This study and associated protocols were conducted 
after approval by the ANU-HREC (HREC identification 
2011/031).
Results
Standing time and WST differ consistently between ME/
CFS and study controls
All 17 healthy controls stood for 20  min, with difficulty 
scores ranging from 0 to 3 (one study control participant 
had a standing difficulty of 8, but did not fulfil the Cana-
dian criteria for a ME/CFS diagnosis).
Thirty-one (31) of the 45 ME/CFS patients stood for 
20  min, with difficulty scores ranging from 1 to 9. The 
remaining 14 stood for between 2 and 18 min with dif-
ficulty scores of 12 or 14, depending on whether standing 
was achieved for less than or greater than 10 min.
The weighted standing time combines standing time 
(ST) with a subjective assessment of standing difficulty. 
The distribution of WST was bimodal for patients, sug-
gesting the existence of moderate and severe degrees of 
ME/CFS. The distribution of WST for healthy controls is 
highly skewed with almost no variation (Fig. 1). Wilcoxon 
signed rank tests (Table 2) showed that there were signifi-
cant differences for both median ST and WST between 
ME/CFS and healthy controls.
WST stratifies ME/CFS severity
The distribution of WST in ME/CFS patients resulted 
in the assignment of three classes to stratify ME/CFS 
severity (mild = 1, moderate = 2, severe = 3) as defined 
by WST (mins), in addition to a class for study controls 
(healthy = 0). Assessment via the Canadian criteria deter-
mined initial assignment as a healthy study control, or 
ME/CFS participant (see “Methods”).
WST differed significantly from class to class for the 
four categories summarised in Table 3 (F = 188.8; df = 3, 
58; p < 0.0001) (and Fig. 2a).
Comparison between ME/CFS and healthy study control 
participant cohorts identified several diagnostic factors 
from the Canadian Consensus Criteria
There were 48 conditions in the Canadian Criteria 
[1] that were interrogated by tetrachoric correlation 
and FA; symptoms that discriminated cases from con-
trols in 100% of cases were not included. Significantly 
higher proportions of ME/CFS participants consistently 
reported the presence of symptoms under the Canadian 
Criteria, except for monthly headache and migraine 
headache, which were not significantly different between 
the cohorts. Unexplained fatigue for 6-months or greater 
(with limited activity), and post-exertional malaise 
and/or fatigue were mandatory for a positive ME/CFS 
diagnosis; all ME/CFS research participants had these 
symptoms, but no healthy study controls. Beyond these 
mandatory diagnostic criteria, 12 significant Canadian 
Criteria symptoms (p < 0.0001) were identified by fac-
tor analysis (Table 1: specific symptoms in italics): Sleep 
disorders (Difficulty Going to Sleep, Sleep during Day), 
Pain (Any Body Region, Headache), Neurological mani-
festations (Light/Sound/Smell Sensitivity, Confusion), 
Autonomic symptoms (Breathless, Arrhythmia), Gut 
symptoms (Bloating/Abdominal Pain/Diarrhoea), Tem-
perature regulation (Hot or Cold Flushes), and Immune 
symptoms (Tender Glands/Flu-like Symptoms, Chemical 
Allergy/Sensitivity).
In terms of the percentage variation in the above symp-
toms explained by factor analysis, pain (any region of 
the body) accounted for 87%. Also under the pain factor, 
headache explained 71% of the symptom variation, but 
was not significantly different across WST categories as 
determined via one-way ANOVA (Table 1). The neuroen-
docrine symptom of poor temperature regulation (Hot or 
Cold Flushes) was also notable explaining 73% of varia-
tion across WST categories, as were the neurological/
cognitive symptoms of Light/Sound/Smell sensitivity at 
62%.
Further details on the parameters and implementation 
of factor analyses (FA) that detected the most predictive 
clinical criteria are available in Additional file  1: Tables 
S3–S10.
These results identified specific symptoms within the 
general clinical domains applied under the Canadian 
Criteria, and as such, simplified the diagnostic criteria 
used to assess the patient. With unexplained and persis-
tent fatigue for 6-months or longer, and post-exertional 
fatigue/malaise as mandatory symptoms, pain (but not 
headache) and poor body temperature regulation were 
the leading ME/CFS symptoms identified from the CFS 
Discovery cohort.
Clinical criteria discriminate levels of ME/CFS severity, 
defined by WST
For the non-mandatory Canadian Criteria identified by 
factor analysis (Table 4), 7–57% of moderate and severe 
ME/CFS participants reported positively, whereas 13% or 
fewer healthy controls reported symptoms within these 
criteria. Therefore, there was a small degree of symptom 
overlap that will require further differentiation on future 
investigation.
Analytes do not differ significantly between ME/CFS 
and Study Controls, except for serum activin B
From among a broad range of pathology test and 
cytokine assay results (Additional file  1: Table S2), only 
serum activin B was significantly different (p < 0.05) for 
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Fig. 1 Comparison of raw standing time, standing difficulty profiles and weighted standing time (WST) for ME/CFS and healthy study controls, 
as performed for the assessment of orthostatic intolerance. a Time standing (minutes), b difficulty (subjective scale from 0 to 14), and c weighted 
standing time (WST) for 45 CFS patients and 17 healthy study controls
Table 3 Definitions of weighted standing time (WST minutes) healthy study controls and ME/CFS classes
Severe case standing difficulty scored as 12 if the CFS/ME participant stood for 10–18 min, and 14 if standing upright was possible for less than (<) 10 min
a Includes 1 healthy control with time = 20 min and difficulty = 8
Class n WST (mins) Definition of category
No ME/CFS (0) 16 15.0–20.0 Did not meet the Canadian Criteria. All stood 20 min with difficulty ranging from 0 to 3
Mild (1) 8 15.0–20.0 Met the Canadian criteria. All stood 20 min with difficulty ranging from 0 to 3
Moderate (2) 24a 6.0–< 15.0 Met the Canadian criteria. All stood 20 min with difficulty ranging from 4 to 10
Severe (3) 14 < 6.0 Met the Canadian criteria. All stood < 20 min with difficulty assigned as 12 or 14
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Fig. 2 Mean (± SEM) serum, urine and cell marker profiles as summarised by weighted standing time (WST), namely, (a) WST (minutes), (b) 24-h 
urine volume (mL/24-h) (c) total white cell count (WCC) (×  109/L) (d) monocytes (×  109/L) (e), lymphocytes (×  109/L) and (f) serum Vitamin D 
(nmol/L). WST classes are: Healthy study controls (0), ME/CFS—mild (1), ME/CFS—moderate (2), and ME/CFS—severe (3) WST class definitions are 
presented in Table 3
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the direct comparison between ME/CFS and study con-
trol (healthy) participants, as previously reported [24]. 
Individual participant serum and urine pathology results 
generally fell within the laboratory reference interval. 
Results of investigating the ability of WST stratification 
to identify significant analyte variation due to orthostatic 
intolerance severity follow.
Five routine pathology markers statistically discriminate 
between levels of ME/CFS severity as defined by WST
One-way ANOVA showed statistically significant differ-
ences in values across the four categories of WST (from 
healthy controls to severe ME/CFS) for five routine 
pathology markers, namely:
Urine volume (p = 0.0009), URINE CREATININE 
(p = 0.0092), monocytes (p = 0.0129), lymphocytes 
(p = 0.0250) and white cell count (p = 0.0381). Serum 
vitamin D, TSH, anion gap and haemoglobin were not 
significantly different across the WST scale (Fig.  2 and 
Additional file: 1).
Figure 2 shows mean WST (± SEM) for several serum 
or urine markers, for example white cell count and 24-h 
urine volume. Mean WST is shown for the four levels of 
ME/CFS severity, to reinforce the discriminatory power 
of the WST. Post-hoc significant differences between 
levels of ME/CFS severity are given in Additional file 1: 
Table S11. The results of other serum markers appear 
in Additional file  1: Figure S1 since they have broader 
importance for general fatigue screening (e.g. haemoglo-
bin, TSH, serum vitamin D). Whether statistically signifi-
cant across the WST severity scale or not, the individual 
and mean values remained within the specific marker 
laboratory reference interval for each WST category.
Figure  3 summarises the WST-associated mean (± 
SEM) serum concentrations for activin family proteins 
(Fig.  3a–c). A statistically significant difference in mean 
values was detected for activin B (F = 3.549; df = 3, 
57; p = 0.02), but not activin A, or the activin-binding 
protein follistatin. Interleukin 10 (IL-10) did not vary 
significantly across WST categories (Fig. 3d), and nor did 
IL-2, IL-4, IL-6 and IFN-γ. TNF and IL-17A were ana-
lysed also, but were not detected in the majority of study 
participant serum samples (results not shown).
Discussion
This study consisted of two primary participant groups: 
healthy (study) controls, and patients who satisfied the 
Canadian criteria for ME/CFS [1]. Comparison of the 
criteria and analytes in those two groups found that no 
routine pathology marker was significantly different at 
p < 0.05, and found no patterns of abnormal results for 
ME/CFS patients when applying standard reference 
intervals [24, 27]. The calculation of a weighted stand-
ing time (WST), which combined the participant’s time 
standing (minutes) with a subjective standing difficulty 
score, measured as a component of orthostatic intol-
erance (OI) assessments by a specialist ME/CFS clinic 
with 20 years’ experience. While OI is not unique to ME/
CFS, the presence of debilitating fatigue for 6-months, or 
longer, and post-exertional fatigue/malaise increases its 
relevance to ME/CFS.
The WST scale, with three levels of ME/CFS severity, 
allowed the detection of significant variation (p < 0.05) 
for a number of routine markers via one-way ANOVA. 
Therefore, this interpretation of pathology data via WST 
response profile provides a new insight in how to uti-
lize pathology data for ME/CFS diagnosis and monitor-
ing, outside of traditional reference interval observation 
practices.
The difficulties of diagnosing ME/CFS and delineating 
its severity are reflected by the twenty-separate clinical/
consensus criteria developed over the years, with the 
1994 Fukuda criteria the most popular in the research 
context [28, 29]. This lack of diagnostic consensus can 
be mitigated by the development of measurable scales, 
like the WST, associated with easily accessible serum/
urine markers that are requested from pathology depart-
ments when assessing patients for ME/CFS. Hornig et al. 
Table 4 Percentage of participants experiencing criteria-defined, non-mandatory symptoms for three levels of ME/CFS 
severity (increasing order of occurrence from healthy/mild to severe cohorts)
All mild to severe cases reported > 6-months fatigue and post exertional malaise
* Statistical significance at p < 0.05
Criterion Healthy/mild % (n = 24) Moderate % (n = 21) Severe % (n = 14) p value (χ2 test)
Headaches monthly 0 14 21 0.0801
Migraine 0 14 7 0.1636
Headaches daily 8 43 28 0.0282*
Sensitive to smell 8 52 57 0.0014*
Sensitive to touch 13 23 36 0.2425
Headaches weekly 13 29 36 0.217
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[30] had success in this regard, with serum cytokine pro-
files separating the ME/CFS cohorts into short-term or 
long-term patients. IFN-γ was the prominent cytokine 
marker separating short—from long-term patients, with 
network and recursive partitioning analyses describing 
the broader relationships between the immune markers 
tested, as well as age. Recent investigations of ME/CFS 
cytokine profiles have shown statistical significance for 
TGF-β and Resistin when compared to matched healthy 
controls, as well as significant correlations of seventeen 
cytokines with disease severity, with thirteen being pro-
inflammatory [31].
Attempts to stratify ME/CFS patients into sub-classes 
has a long history, and past efforts have also included 
immune responses [32], including in the context of sleep 
or exercise deprivation [33]. Comorbidity with postural 
orthostatic tachycardia syndrome (POTS) has been also 
considered when looking to further classify ME/CFS 
symptoms, including in terms of neurohumoral and 
haemodynamic profiles [34]. According to Reynolds et al. 
[10], patients with comorbid POTS were significantly 
younger, and thus had symptoms for a shorter period, 
had greater standing task difficulty, and significant vari-
ations in autonomic functioning. These features were 
identified in 11% of a retrospective cohort comprising 
306 CFS Discovery patients, similar to that identified by 
a British study [35].
Vitamin D deficiency is a well-known outcome for the 
bed-bound, as is often the case in severe cases of ME/
CFS [36]. The observable, but statistically non-significant 
drop in Vitamin D levels observed in this study as ME/
CFS severity increases, suggests that vitamin D deficiency 
Fig. 3 Mean (± SEM) serum concentrations of activin proteins and a representative cytokine as summarised by weighted standing time (WST), 
namely, (a) activin A (pg/mL), (b) activin B (pg/mL), (c) follistatin (ng/mL), and (d) interleukin-10 (IL-10) (pg/mL). WST classes are: Healthy study 
controls (0), ME/CFS—mild (1), ME/CFS—moderate (2), and ME/CFS—severe (3) WST class definitions are presented in Table 3
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is not a contributor to ME/CFS symptoms, or severity, 
for this cohort. Likewise, Thyroid Stimulating Hormone 
(TSH) does not vary significantly between WST catego-
ries. Similarly, haemoglobin was not significantly differ-
ent. In contrast, the statistically significant change in 
24-h urine volume for differing levels of ME/CFS severity 
was observed, consistent with the anomalies in a larger 
cross-sectional study [27]. IL-10 has been implicated in 
the pathogenesis of ME/CFS [37, 38], but there is no evi-
dence from this study for a relationship between IL-10 
levels and presence/severity of ME/CFS symptoms. On 
the other hand, Activin B has been recently identified as 
significant when separating this ME/CFS cohort from the 
same study (healthy) controls, [24] a relationship that was 
also reflected by WST analysis.
Factor analysis of ME/CFS symptoms in children [39] 
identified three factors that were subsequently referred 
to as phenotypes: musculoskeletal, migraine and sore 
throat. Our research has identified a larger set of fac-
tors, which may be due to the more complex nature of 
ME/CFS in adults, or the nature of the criteria used to 
assess ME/CFS in each study. Outside of the manda-
tory 6-months unexplained fatigue and post-exertional 
malaise, body pain (not headache) and temperature regu-
lation perturbations explained 87 and 73%, respectively, 
of variation across the WST spectrum from healthy to 
severe ME/CFS symptoms (for this study defined as par-
ticipants who were unable to stand for 20 min).
Strengths of this study emphasise the innovative use 
of standing time and difficulty to construct the WST, 
and from there derive the three categories of ME/CFS 
severity. The richness of the data set, Canadian Crite-
ria responses and predictions associated with routinely 
available pathology test results, are also strengths in rela-
tion to clinical translation. However, the study is limited 
by its moderate sample size, which particularly limited 
the acuity of the factor analyses to completely separate 
clinical criteria. The number of healthy controls is also 
small. Unpublished analysis from a separate cohort of 
healthy controls is incomplete at present, but thus far 
confirms the results in this paper. Additionally, the ST is 
only run once per patient due to the clinical context of 
the fatigued patients and the potentially taxing nature of 
the test. Future research can focus on accessing histori-
cal data in order to increase sample sizes, repeating tests 
where clinically possible, making use of longitudinal data 
on patients over time, or undertaking an independent 
validation with a larger cohort across more locations.
Conclusions
Myalgic Encephalomyelitis/Chronic Fatigue Syndrome is 
a disabling yet prevalent condition, and its pathophysiol-
ogy is poorly understood. This study further defined the 
key symptoms of the syndrome in an Australian sample 
recruited from the greater Melbourne area of Victoria, 
as well as identified analyte patterns unique to ME/CFS. 
Investigations of ME/CFS pathogenesis were conducted 
through investigation of biochemical, immunological, 
haematological and endocrine data, with supporting clin-
ical examination and participant survey data utilised.
Importantly we have shown that WST is a useful 
measure of ME/CFS severity, and easy to implement in 
clinical environments. Its usefulness could be further 
enhanced by recording the exact time standing rather 
than one rounded to the nearest 2 min. A difficulty score 
recorded every 2 min would also be a very rich source of 
data, as would a standard rubric for clinicians or patients 
to record difficulty. The enhanced understanding of the 
behaviour of the ST and WST from this study will sup-
port a greater use of this simple test as a component of 
ME/CFS assessment, for future diagnosis and treatment.
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